期刊
FUTURE ONCOLOGY
卷 13, 期 19, 页码 1665-1668出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0237
关键词
drug development; drug resistance; hepatocellular carcinoma; next generation sequencing; recurrence; regorafenib; survival